Shanghai Recombinant Vaccine and New Adjuvant Technology Innovation Center Project

The Shanghai Recombinant Vaccine and New Adjuvant Technology Innovation Center is a specialized biotechnology entity focused on the research, development, and industrialization of advanced vaccine candidates. Operating under the umbrella of the Shanghai Institute of Biological Products (SIBP) and the China National Biotec Group (Sinopharm), the center serves as a critical hub for recombinant protein technology and novel adjuvant systems. Its portfolio is highlighted by the development of the NVSI-06-07 recombinant COVID-19 vaccine, which utilizes a trimeric spike protein design. The center integrates high-throughput screening, structural biology, and pilot-scale manufacturing to address emerging infectious diseases. By combining proprietary adjuvant formulations with recombinant antigens, the center aims to enhance the immunogenicity and stability of next-generation vaccines for global public health.